Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Rick Graham - Senior Vice President of Research and Development Aziz Sawaf - Chief Financial Officer Conference Call Participants David Risinger - SVB Securities Jingming Chen - Evercore Divya Rao - TD Cowen Operator Ladies and gentlemen, good afternoon. I’d like to welcome everyone to the Theravance Biopharma F ...

Approved incremental $75M to existing $250M program initiated Sept'22, with goal to complete program by end of 2023 Prioritize resource allocation toward ampreloxetine Phase 3 study and YUPELRI® (revefenacin) PIFR-2 study PIFR, peak inspiratory flow rate. AGM, Annual General Meeting – May 2, 2023 ‣ Submit orphan drug designation request in early 2023 ‣ $50M potential milestone for TRELEGY Net Sales of ~$2.86B2 Co-promotion agreement with VIATRISTM (35% / 65% Profit Share) Net sales increased 27% Q4'22 vs. Q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033 SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: NONE Indicate by check mark if the registrant is a w ...

Theravance Biopharma Inc. (NASDAQ:TBPH) Q4 2022 Results Conference Call February 27, 2023 5:00 PM ET Company Participants Rick Winningham - Chairman and Chief Executive Officer Rhonda Farnum - Senior Vice President, Chief Business Officer Rick Graham - Senior Vice President, Research and Development Aziz Sawaf - Chief Financial Officer Conference Call Participants David Risinger - SVB Securities Douglas Tsao - H.C. Wainwright Eva Privitera - Cowen Vikram Purohit - Morgan Stanley Liisa Bayko - Evercore ISI O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98 ...

| --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | Third Quarter 2022 Financial Results and Business Update | | | November 7, 2022 | | | THERAVANCE BIOPHAR ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Douglas Tsao – H.C. Wainwright Joseph Stringer – Needham Brian Skorney – Baird David Risinger – SVB Securities Operato ...

| --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | Transformed and Focused on Medicines that Make a Difference | | | September 13, 2022 | | | THERAVANCE BI ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-1226 ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Gail Cohen – Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance B ...